Beta Bionics, Inc. BBNX
17.81 USD +1.29 (+7.81%)
At closeNov 11, 2026, 4:01 PM EST
17.81 0.00 0.00%
After hours · Nov 11, 4:01 PM ET
16.77 Day range 17.91
8.80 52-week range 32.71
- YTD
- -41.55%
- 1 year
- -38.20%
News
fool.com Beta Bio: 3 Key Takeaways for Long-Term Investors A tubeless patch pump launch and pharmacy channel momentum could reshape the company's margin profile within three years.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
benzinga.com TD Cowen Maintains Hold on Beta Bionics, Raises Price Target to $21 TD Cowen analyst Mathew Blackman maintains Beta Bionics (NASDAQ:BBNX) with a Hold and raises the price target from $18 to $21.
benzinga.com Piper Sandler Reiterates Overweight on Beta Bionics, Raises Price Target to $24 Piper Sandler analyst Matt O'Brien reiterates Beta Bionics (NASDAQ:BBNX) with a Overweight and raises the price target from $20 to $24.
benzinga.com Beta Bionics Q3 2026 Earnings Call Transcript Beta Bionics (NASDAQ:BBNX) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Neumora Therapeutics (NASDAQ:NMRA) shares rose 11.9% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $73.8 million. Pulmonx (NASDAQ:LUNG)…
benzinga.com Beta Bionics Raises FY2026 Sales Guidance from $121.000M-$126.000M to $124.000M-$126.000M vs $126.626M Est Beta Bionics (NASDAQ:BBNX) raises FY2026 sales outlook from $121.000 million-$126.000 million to $124.000 million-$126.000 million vs $126.626 million estimate.- benzinga.com Beta Bionics Q3 EPS $(0.52) Beats $(0.53) Estimate, Sales $35.505M Beat $34.722M Estimate Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.53) by 1.89 percent. This is a 57.58 percent decrease over losses of $(0.33)…
- benzinga.com Jefferies Initiates Coverage On Beta Bionics with Buy Rating, Announces Price Target of $30 Jefferies analyst Michael Toomey initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Buy rating and announces Price Target of $30.
benzinga.com Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $28 Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $23 to $28.- benzinga.com Wells Fargo Initiates Coverage On Beta Bionics with Overweight Rating, Announces Price Target of $28 Wells Fargo analyst Larry Biegelsen initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Overweight rating and announces Price Target of $28.
benzinga.com LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday U.S. stocks mixed as Nasdaq rises; LuxExperience jumps 13.5% on strong sales, while Einride, Forgent, Cipher and others post gains.
benzinga.com Beta Bionics, J.B. Hunt Transport And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures rose, but Beta Bionics fell 7.1% after pricing a stock offering; several other stocks also declined in premarket trading.- benzinga.com Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket Tempest shares surged 49.6% on a Senlang CD7 CAR-T option deal, while several small-cap stocks posted sharp premarket gains and losses.
- benzinga.com Beta Bionics Announces Proposed $125M Public Offering Of Common Stock Beta Bionics, Inc. (NASDAQ:BBNX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $125.0 million of shares of its…
benzinga.com Truist Securities Reiterates Buy on Beta Bionics, Raises Price Target to $23 Truist Securities analyst Richard Newitter reiterates Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $22 to $23.- benzinga.com Baird Maintains Neutral on Beta Bionics, Raises Price Target to $16 Baird analyst Jeff Johnson maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and raises the price target from $14 to $16.
- benzinga.com Beta Bionics Receives FDA Clearance For Its Mint Pump That Requires No Recharging And Integrates With Industry-Leading Continuous Glucose Monitors; Lowers FY26 Sales Guidance From $131M-$136M To $121M-$126M Reflecting Potential Revenue Deferral Impact Of Up To $10M In Q4 As New Prospective iLet Users Could Choose To Await The Launch Of Mint Mint enables smartphone control for iOS and Android users. Mint is expected to meaningfully expand the Company’s addressable insulin delivery market, particularly among people with diabetes seeking a…
benzinga.com Senseonics Partners With Beta Bionics To Integrate Its Eversense 365 CGM With Beta Bionics’ iLet Bionic Pancreas Automated Insulin Delivery System The companies are collaborating to integrate Eversense® 365 CGM with Beta Bionics’ iLet® Bionic Pancreas automated insulin delivery (AID) system designed to simplify diabetes management. The…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 49.2% to $7.91 during Friday's pre-market session. The company's market cap stands at $3.5 million. Biodexa Pharmaceuticals (NASDAQ:BDRX)…
benzinga.com FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.- benzinga.com William Blair Initiates Coverage On Beta Bionics with Market Perform Rating William Blair analyst Steven Lichtman initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Market Perform rating.
benzinga.com Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics William Blair initiates coverage on Tandem Diabetes Care and Beta Bionics, highlighting their growth potential in the insulin pump market.- benzinga.com Beta Bionics Affirms FY2026 Sales Guidance of $131.000M-$136.000M vs $133.305M Est Beta Bionics (NASDAQ:BBNX) affirms FY2026 sales outlook from $131.000 million-$136.000 million to $131.000 million-$136.000 million vs $133.305 million estimate.
benzinga.com Beta Bionics Q2 EPS $(0.53) Beats $(0.56) Estimate, Sales $32.013M Beat $31.443M Estimate Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.56) by 5.36 percent. This is a 35.9 percent decrease over losses of $(0.39)…- benzinga.com Goldman Sachs Maintains Buy on Beta Bionics, Raises Price Target to $19 Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $17 to $19.
benzinga.com Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $22 Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $18 to $22.- benzinga.com Beta Bionics Announces Near Real-Time Real-World Data On iLet Bionic Pancreas Is Now Publicly Available At betabionics.com/hcp/real-world-data Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that near real-time real-world data on the iLet Bionic Pancreas is…
- benzinga.com Goldman Sachs Maintains Buy on Beta Bionics, Lowers Price Target to $17 Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $19 to $17.
- benzinga.com Beta Bionics Intends To Fully Commercialize Mint By Q2 2027 Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it expects to fully commercialize Mint by the end of the…
- benzinga.com B of A Securities Maintains Neutral on Beta Bionics, Lowers Price Target to $11 B of A Securities analyst Travis Steed maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and lowers the price target from $23 to $11.
- benzinga.com Leerink Partners Maintains Outperform on Beta Bionics, Lowers Price Target to $24 Leerink Partners analyst Mike Kratky maintains Beta Bionics (NASDAQ:BBNX) with a Outperform and lowers the price target from $25 to $24.
- benzinga.com Stifel Maintains Buy on Beta Bionics, Lowers Price Target to $20 Stifel analyst Jonathan Block maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $22 to $20.
- benzinga.com Beta Bionics Q1 2026 Earnings Call Transcript
- benzinga.com Beta Bionics Raises FY2026 Sales Guidance from $130.000M-$135.000M to $131.000M-$136.000M vs $132.590M Est Beta Bionics (NASDAQ:BBNX) raises FY2026 sales outlook from $130.000 million-$135.000 million to $131.000 million-$136.000 million vs $132.590 million estimate.
- benzinga.com Beta Bionics Q1 EPS $(0.49), Inline, Sales $27.626M Beat $26.965M Estimate Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.49) per share which met the analyst consensus estimate. This is a 47.31 percent increase over losses of $(0.93) per share from the same…
benzinga.com Earnings Scheduled For April 21, 2026 
benzinga.com Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt rose on news of being acquired by Somnigroup.
benzinga.com Goldman Sachs Maintains Buy on Beta Bionics, Lowers Price Target to $20 Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $23 to $20.- benzinga.com Stifel Maintains Buy on Beta Bionics, Lowers Price Target to $22 Stifel analyst Jonathan Block maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $25 to $22.
benzinga.com Expert Outlook: Beta Bionics Through The Eyes Of 7 Analysts - benzinga.com Baird Maintains Neutral on Beta Bionics, Lowers Price Target to $14 Baird analyst Jeff Johnson maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and lowers the price target from $28 to $14.
- benzinga.com Beta Bionics Sees FY2026 Sales $130.000M-$135.000M vs $132.717M Est Beta Bionics (NASDAQ:BBNX) sees FY2026 sales of $130.000 million-$135.000 million vs $132.717 million analyst estimate.
- benzinga.com Beta Bionics Q4 EPS $(0.30) Beats $(0.42) Estimate, Sales $32.121M Beat $30.243M Estimate Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.42) by 28.06 percent. This is a 88.97 percent increase over losses of…
- benzinga.com Earnings Scheduled For February 17, 2026
benzinga.com Earnings Preview For Beta Bionics - benzinga.com Stifel Maintains Buy on Beta Bionics, Lowers Price Target to $25 Stifel analyst Jonathan Block maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $31 to $25.
- benzinga.com Truist Securities Maintains Buy on Beta Bionics, Lowers Price Target to $25 Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $37 to $25.
- benzinga.com Beta Bionics Receives FDA Warning Letter Citing Quality System Deficiencies At California Facility On January 29, 2026, Beta Bionics, Inc. (the "Company") received a warning letter (the "Warning Letter") from the U.S. Food and Drug Administration (the "FDA") following inspection of the Company's…
- benzinga.com Beyond The Numbers: 4 Analysts Discuss Beta Bionics Stock